secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001193125-25-194948
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products
--------------------------------------------------------------------------------

- Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.
- Reduced rate also applies to Product Payment damages received during the royalty period.
- Company has suspended clinical development and commercial readiness for both products.
- Purchaser is Blackstone Life Sciences, successor in interest to Clarus Ventures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/0001193125-25-194948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/d478971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-194948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer